Merrimack Pharmaceuticals Inc MACK:NASDAQ

RT Quote | Last NYSE, VOL From CTA | USD
Last | 3:12 PM EDT
15.12quote price arrow up+0.05 (+0.33%)
Volume
137,756
52 week range
11.53 - 15.89
Loading...
  • Open15.08
  • Day High15.13
  • Day Low15.08
  • Prev Close15.07
  • 52 Week High15.89
  • 52 Week High Date02/13/24
  • 52 Week Low11.53
  • 52 Week Low Date07/19/23

Key Stats

  • Market Cap219.72M
  • Shares Out14.53M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.41
  • YTD % Change12.79

KEY STATS

  • Open15.08
  • Day High15.13
  • Day Low15.08
  • Prev Close15.07
  • 52 Week High15.89
  • 52 Week High Date02/13/24
  • 52 Week Low11.53
  • 52 Week Low Date07/19/23
  • Market Cap219.72M
  • Shares Out14.53M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.41
  • YTD % Change12.79

RATIOS/PROFITABILITY

  • EPS (TTM)-0.08
  • P/E (TTM)-183.05
  • Fwd P/E (NTM)-4.70
  • EBITDA (TTM)-2.176M
  • ROE (TTM)-6.22%
  • Revenue (TTM)-
  • Gross Margin (TTM)94.58%
  • Net Margin (TTM)-159.70%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Merrimack Pharmaceuticals Inc

 

Profile

MORE
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food...
Gary Crocker
Chairman of the Board, President, Treasurer
Address
One Broadway, 14Th Floor
Cambridge, MA
02142
United States

Top Peers

SYMBOLLASTCHG%CHG
OVID
Ovid Therapeutics Inc
3.01-0.04-1.31%
PRLD
Prelude Therapeutics Inc
3.71-0.36-8.82%
DSGN
Design Therapeutics Inc
4.63-0.13-2.83%
ABOS
Acumen Pharmaceuticals Inc
3.40-0.17-4.90%
TRVI
Trevi Therapeutics Inc
2.69-0.23-7.71%